Moderna

At Moderna, our mission is to deliver the greatest possible impact to people through messenger RNA (mRNA) medicines. mRNA acts as a messenger, using the body’s own mechanisms to help prevent and treat disease.

Since 2010, Moderna has been researching and developing mRNA-based medicines across a range of areas, including infectious disease, immuno-oncology, rare diseases, cardiovascular disease, and autoimmune disorders. The company’s work in mRNA technology supported the development of an authorised vaccine used during the COVID-19 pandemic.

In December 2022, Moderna entered into a ten-year strategic partnership with the UK Government to establish a state-of-the-art mRNA research, development and manufacturing facility at the Harwell Science and Innovation Campus in Oxfordshire.

Officially opened in September 2025, the Moderna Innovation and Technology Centre (MITC) is the first facility in the UK designed to manufacture an onshore supply of mRNA vaccines to support NHS vaccination programmes. The site employs more than 150 people and is capable of producing up to 100 million mRNA vaccine doses per year, with the ability to scale up to 250 million doses in the event of a pandemic, supporting the UK’s health resilience.

The MITC also houses Clinical R&D laboratories that analyse samples from Moderna’s global clinical trials. Through its partnership with the UK, Moderna has supported more than 20 clinical trials across 110 sites nationwide, making it the country’s largest commercial sponsor of trials in 2023/24.

The MITC is part of a global network of advanced manufacturing hubs, alongside facilities in Australia and Canada, which collectively enhance preparedness and response capacity for future health challenges.